Effectiveness and cost effectiveness of pharmacological thromboprophylaxis for medical inpatients: decision analysis modelling study.
Sarah DavisSteve GoodacreDaniel Edward HornerAbdullah PandorMark HollandKerstin de WitBeverley Jane HuntXavier Luke GriffinPublished in: BMJ medicine (2024)
Offering pharmacological thromboprophylaxis to all eligible medical inpatients appears to be the most cost effective strategy. To be cost effective, any risk assessment model would need to have a very high sensitivity resulting in widespread thromboprophylaxis in all patients except those at the very lowest risk, who could potentially avoid prophylactic anticoagulation during their hospital stay.
Keyphrases
- venous thromboembolism
- risk assessment
- healthcare
- end stage renal disease
- direct oral anticoagulants
- ejection fraction
- newly diagnosed
- randomized controlled trial
- chronic kidney disease
- systematic review
- peritoneal dialysis
- emergency department
- human health
- heavy metals
- patient reported outcomes
- adverse drug
- patient reported